Last 7 days
Bookmark and Share    
Full Text
Peer Reviewed
See detailIs there a specific pattern of lean/fat mass ratio in sarcopenic subjects?
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Croisier, Jean-Louis ULg et al

in Osteoporosis International (2015), 26(1), 261

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailOcanacatib antifracture efficacy and saftey in postmenopausal women with osteoporosis: results from the phase III long-term adonacatib fracture trial (LOFT)
McClung, MR; Langdahl, B; Papapoulos, S et al

in Osteoporosis International (2015), 26(1), 1

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailDenosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension
Papapoulos, S; Roux, C; Bone, HG et al

in Osteoporosis International (2015), 26(1), 4

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailThe position of Strontium ranelate in today's management of osteoporosis
Reginster, Jean-Yves ULg; Brandi, ML; Cannata-Andia, J et al

in Osteoporosis International (2015), 26(1), 5

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailCritical evaluation of promising markers for sarcopenia
CAVALIER, Etienne ULg; GADISSEUR, Romy ULg; GEBOES, Séverine ULg et al

in Osteoporosis International (2015), 26(1), 25

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailTrabecular bone score (TBS) as a new complementary appproach for osteoporosis evaluation in clinical practice
Harvey, NC; Binkley, N; Brandi, ML et al

in Osteoporosis International (2015), 26(1), 7

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailPrevalence of frailty in nursing home residents according to various diagnostic tools
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; Dardenne, Nadia ULg et al

in Osteoporosis International (2015), 26(1), 290

Detailed reference viewed: 11 (3 ULg)
Full Text
Peer Reviewed
See detailGlucosamine and chondroitin salts in the management of osteoarthritis in Europe
Reginster, Jean-Yves ULg

in Osteoporosis International (2015), 26(1), 8

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailCan we identify patients to be treated in osteoarthritis?
Arden, NK; Richette, P; Cooper, C et al

in Osteoporosis International (2015), 26(1), 10

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the registration of drugs to treat sarcopenia
Reginster, Jean-Yves ULg; Cooper, C; Rizzoli, R et al

in Osteoporosis International (2015), 26(1), 11

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailClinical components linked to sarcopenia: the sarcophage study
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Petermans, Jean ULg et al

in Osteoporosis International (2015), 26(1), 258

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailGrip fatigue resistance and self-perceived fatigue in relation with sarcopenia and quality of life
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Bautmans, I et al

in Osteoporosis International (2015), 26(1), 265

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailAnti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.
Esser, Nathalie ULg; Paquot, Nicolas ULg; Scheen, André ULg

in Expert opinion on investigational drugs (2015), 24(3), 283-307

Introduction: There is a growing body of evidence to suggest that chronic silent inflammation is a key feature in abdominal obesity, metabolic syndrome, type 2 diabetes (T2DM) and cardiovascular disease ... [more ▼]

Introduction: There is a growing body of evidence to suggest that chronic silent inflammation is a key feature in abdominal obesity, metabolic syndrome, type 2 diabetes (T2DM) and cardiovascular disease (CVD). These observations suggest that pharmacological strategies, which reduce inflammation, may be therapeutically useful in treating obesity, type 2 diabetes and associated CVD. Area covered: The article covers novel strategies, using either small molecules or monoclonal antibodies. These strategies include: approaches targeting IKK-b-NF-kB (salicylates, salsalate), TNF-alpha (etanercept, infliximab, adalimumab), IL-1beta (anakinra, canakinumab) and IL-6 (tocilizumab), AMP-activated protein kinase activators, sirtuin-1 activators, mammalian target of rapamycin inhibitors and C-C motif chemokine receptor 2 antagonists. Expert opinion: The available data supports the concept that targeting inflammation improves insulin sensitivity and beta-cell function; it also ameliorates glucose control in insulin-resistant patients with inflammatory rheumatoid diseases as well in patients with metabolic syndrome or T2DM. Although promising, the observed metabolic effects remain rather modest in most clinical trials. The potential use of combined anti-inflammatory agents targeting both insulin resistance and insulin secretion appears appealing but remains unexplored. Large-scale prospective clinical trials are underway to investigate the safety and efficacy of different anti-inflammatory drugs. Further evidence is needed to support the concept that targeting inflammation pathways may represent a valuable option to tackle the cardiometabolic complications of obesity. [less ▲]

Detailed reference viewed: 25 (4 ULg)
Full Text
Peer Reviewed
See detailHealth related quality of life in sarcopenia
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Osteoporosis International (2015), 26(1), 266

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailPercentage of women achieving non-osteoporotic BMD T-scores at the lumbar spine (LS) and total hip (TH) during up to 8 years of Denosumab (Dmab) treatment
Ferrari, S; Libanati, C; Lin, CJF et al

in Osteoporosis International (2015), 26(1), 268

Detailed reference viewed: 9 (1 ULg)